B

    Bioatla Inc (BCAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.74
    -1.40 (-44.75%)

    Market Cap: $2.89M

    Last updated: Aug 28, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(14/23)
    Avg Surprise
    -82.86%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$0.14N/A+101.65%Beat+145.2%
    Mar 26
    		$-4.22$-0.20-2012.35%Miss+67.5%
    Dec 25
    		$0.00N/A+100.00%Beat+100.0%
    Sep 25
    		$-13.50$-14.83+8.97%Beat-22.7%
    Jun 25
    		$-0.31$-0.29-6.90%Miss+98.6%
    Mar 25
    		$-13.00$-14.67+11.38%Beat+45.8%
    Dec 24
    		$-0.30$-0.38+21.05%Beat+46.5%
    Sep 24
    		$-11.00$-18.50+40.54%Beat+68.6%
    Jun 24
    		$-22.00$-23.00+4.35%Beat+41.3%
    Mar 24
    		$-24.00$-27.12+11.50%Beat+17.2%
    Dec 23
    		$-0.56$-0.79+29.04%Beat+11.0%
    Sep 23
    		$-35.00$-39.87+12.21%Beat-1.4%
    Jun 23
    		$-37.50$-32.10-16.82%Miss+2.6%
    Mar 23
    		$-29.00$-31.20+7.05%Beat+10.8%
    Dec 22
    		$-0.63$-0.70+10.00%Beat-1.6%
    Sep 22
    		$-34.50$-40.80+15.44%Beat+1.0%
    Jun 22
    		$-38.50$-33.83-13.80%Miss+14.4%
    Mar 22
    		$-32.50$-31.50-3.17%Miss-16.1%
    Dec 21
    		$-0.62$-0.63+1.59%Beat+58.7%
    Sep 21
    		$-34.85$-22.83-52.65%Miss-4098.8%
    Jun 21
    		$-45.00$-28.00-60.71%Miss-
    Mar 21
    		$-28.00$-23.00-21.74%Miss-
    Dec 20
    		$-1.50$-0.78-92.31%Miss-
    Sep 20
    		$-0.83$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.10EV/EBITDA0.31x
    Price/FCF-0.12xFCF Yield-815.03%
    Profitability
    Profit Margin0.00%Operating Margin3.49%
    ROE-814.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.20xQuick Ratio0.20x
    Trading Statistics
    Beta0.76Avg Volume121.41K
    52-Week High$71.5052-Week Low$1.51

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.04
    SMA 20$3.20
    SMA 50$3.53
    SMA 200$12.79
    EMA 10$2.95
    EMA 20$3.14
    EMA 50$3.56
    EMA 200$9.91

    MACD

    Line: -0.22Signal: -0.14Hist: -0.08

    ADX

    ADX: 16.8+DI: 14.2-DI: 34.9

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down100.0
    PSAR$4.00

    Bollinger Bands

    Upper Band$3.94
    Lower Band$2.46
    %B Position4612%(Upper)
    Band Width-0.49

    RSI (14-Day)

    Oversold
    20.1

    Momentum Oscillators

    Stoch %K20.9
    Stoch %D28.6
    Williams %R-91.0
    ROC (10d)-43.9%
    Momentum-1.35
    CCI (20d)-494.9
    MFI (14d)27.2

    Volatility Measures

    ATR (14d)$0.44(25.2%)
    StdDev (20d)0.37
    Hist Vol166.8%(High)

    Volume Flow

    VWAP$1.78
    OBV-41.2M
    AD Line245.3B
    CMF (20d)-0.169

    Volume Metrics

    Avg Vol (20d)131.7K
    Vol Ratio7.9x(High)
    VWMA (20d)$2.66

    Pivot Points

    R3$3.41
    R2$3.33
    R1$3.23
    Pivot Point$3.15
    S1$3.06
    S2$2.98
    S3$2.88

    Advanced Oscillators

    TSI-24.85
    Ultimate Osc28.0
    KST-145.86

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$6.50M$0$2.00M$0$0$0$0$11.00M$0$0$1.71M$0
    Cost of Revenue$0$0$-806,000$0$0$0$11.65M$0$0$0$368,000$0
    Gross Profit$6.50M$0$2.00M$0$0$0$-11,650,000$11.00M$0$0$-368,000$0
    Operating Expenses$6.27M$9.33M$11.26M$13.79M$18.65M$17.61M$16.24M$22.27M$21.97M$24.46M$28.54M$35.02M
    R&D$3.34M$4.58M$8.00M$9.54M$13.68M$12.36M$11.65M$16.39M$16.20M$18.85M$22.67M$28.40M
    SG&A$2.93M$4.75M$3.26M$4.25M$4.96M$5.26M$4.59M$5.88M$5.77M$5.61M$5.86M$6.62M
    Operating Income$227,000$-9,308,000$-9,255,000$-13,789,000$-18,647,000$-17,614,000$-16,244,000$-11,270,000$-21,972,000$-24,457,000$-28,536,000$-35,020,000
    Interest Income$16,000$37,000$77,000$133,000$233,000$400,000$554,000$692,000$900,000$1.22M$1.64M$1.73M
    Interest Expense$0$0$532,000$1.99M$64,000$0$0$0$0$0$0$0
    Income Before Tax$452,000$-6,307,000$-9,787,000$-15,775,000$-18,711,000$-15,334,000$-14,884,000$-10,586,000$-21,072,000$-23,234,000$-26,925,000$-33,325,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$452,000$-6,344,000$-9,784,000$-15,778,000$-18,711,000$-15,334,000$-14,884,000$-10,586,000$-21,072,000$-23,234,000$-26,925,000$-33,325,000
    EBITDA$436,000$-6,224,000$-9,845,000$-15,852,000$-18,829,000$-15,551,000$-15,210,000$-11,050,000$-21,743,000$-24,217,000$-28,195,000$-34,789,000
    EBIT$436,000$-6,344,000$-9,864,000$-15,908,000$-18,944,000$-15,734,000$-15,438,000$-11,278,000$-21,972,000$-24,457,000$-28,563,000$-35,059,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BCAB

    News

    BioAtla, Inc. Q2 2026: Revenue $6.5M, EPS $0.27— 10-Q Summary

    BioAtla, Inc. reported second-quarter 2026 results, showing revenue of $6.5 million and diluted EPS of $0.27, a significant improvement from the prior year's net loss and zero revenue. The company is undergoing a strategic review to maximize shareholder value, pausing clinical development, and implementing workforce reductions to preserve capital. Funding constraints are leading to a re-evaluation of program timing and the pursuit of strategic transactions.

    TradingView•8/13/26•
    Somewhat-Bullish

    Bioatla Inc (BCAB) Stock News Today

    This article provides an update on Bioatla Inc (BCAB) stock news, earnings, analyst ratings, and key developments. As of August 7th, BCAB closed at $3.460, up 3.90%. The report indicates that more news is expected soon regarding the company.

    TradingKey•8/8/26•
    Neutral

    Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates

    Bioatla Inc (BCAB) has an earnings forecast score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. Analysts have a consensus price target of USD 10.00 and a "Strong Buy" rating for the stock. The company's previous quarter's EPS was USD -8.18, with an expected EPS of USD -0.17 for the next quarter.

    TradingKey•8/8/26•
    Bullish

    BCAB Q2'26 Earnings: EPS estimate is (8.50) USD

    BioAtla, Inc. (BCAB) is scheduled to release its Q2'26 earnings on August 6th. Analysts estimate revenue to be $0 with an earnings per share (EPS) of ($8.50). This report provides a quick overview of estimated vs. reported EPS for previous quarters.

    TradingView•8/6/26•
    Somewhat-Bearish

    BCAB Q2'26 Earnings: revenue estimate is 0 USD

    BioAtla, Inc. (BCAB) is scheduled to release its Q2'26 earnings on August 6, 2026, at 8:00 AM ET (12:00 PM UTC). The company's revenue estimate for the quarter is $0 USD, with an anticipated EPS (earnings per share) of ($8.50) USD.

    TradingView•7/30/26•
    Neutral

    Frequently Asked Questions About BCAB

    Does BCAB pay dividends?
    Bioatla Inc (BCAB) does not currently pay a regular dividend.
    What is BCAB's market cap?
    Bioatla Inc (BCAB) has a market capitalization of $2.89M with a current stock price of $1.74.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In